12943_2024_2010_MOESM1_ESM.tif (4.12 MB)

Additional file 1 of RICTOR/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF/MEK inhibition

figure

posted on 2024-05-17, 03:40 authored by Luca Ponzone, Valentina Audrito, Claudia Landi, Enrico Moiso, Chiara Levra Levron, Sara Ferrua, Aurora Savino, Nicoletta Vitale, Massimiliano Gasparrini, Lidia Avalle, Lorenza Vantaggiato, Enxhi Shaba, Beatrice Tassone, Stefania Saoncella, Francesca Orso, Daniele Viavattene, Eleonora Marina, Irene Fiorilla, Giulia Burrone, Youssef Abili, Fiorella Altruda, Luca Bini, Silvia Deaglio, Paola Defilippi, Alessio Menga, Valeria Poli, Paolo Ettore Porporato, Paolo Provero, Nadia Raffaelli, Chiara Riganti, Daniela Taverna, Federica Cavallo, Enzo Calautti

Supplementary Material 1

Funding

Fondazione AIRC per la ricerca sul cancro ETS Università di Siena, PIANO DI SOSTEGNO ALLA RICERCA (PSR) 2022-Curiosity-driven (F-CUR) Fondazione Ricerca Molinette Ministero della Salute Fondazione CRT Unione Europea-NextGenerationEU PNRR M4C2-Investimento 1.4-CN00000041 Compagnia di San Paolo National Center for Gene Therapy and Drugs based on RNA Technology, Spoke2, PNRR M4C2-Investimento 1.4-CN00000041 Banca d’Italia

History

Usage metrics

Keywords

mTORC2 RICTOR NAMPT Drug resistance Targeted therapy BRAFV600E melanoma Mitochondrial metabolism

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM